These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33206290)

  • 1. Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer.
    Prakash I; Thomas SM; Greenup RA; Plichta JK; Rosenberger LH; Hyslop T; Fayanju OM
    Breast Cancer Res Treat; 2021 Apr; 186(2):535-550. PubMed ID: 33206290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients.
    Omarini C; Guaitoli G; Noventa S; Andreotti A; Gambini A; Palma E; Papi S; Tazzioli G; Balduzzi S; Dominici M; Cascinu S; Piacentini F
    Eur J Surg Oncol; 2017 Apr; 43(4):613-618. PubMed ID: 27793416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to surgery following neoadjuvant chemotherapy for breast cancer impacts residual cancer burden, recurrence, and survival.
    Sutton TL; Schlitt A; Gardiner SK; Johnson N; Garreau JR
    J Surg Oncol; 2020 Dec; 122(8):1761-1769. PubMed ID: 33125715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
    Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
    Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of wait time from neoadjuvant chemotherapy to surgery in breast cancer: Does time to surgery affect patient outcomes? : Time from Neoadjuvant Chemotherapy to Surgery.
    Lai V; Hajjaj O; Le D; Shokoohi A; Chia S; Simmons C
    Breast Cancer Res Treat; 2020 Dec; 184(3):755-762. PubMed ID: 33001336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of the multidisciplinary team in the decision-making process of patients undergoing neoadjuvant chemotherapy for breast cancer.
    Fancellu A; Pasqualitto V; Cottu P; Giuliani G; Grasso L; Ariu ML; Porcu A; Sanna V
    Updates Surg; 2024 Sep; 76(5):1919-1926. PubMed ID: 38315320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
    Golshan M; Cirrincione CT; Sikov WM; Carey LA; Berry DA; Overmoyer B; Henry NL; Somlo G; Port E; Burstein HJ; Hudis C; Winer E; Ollila DW;
    Breast Cancer Res Treat; 2016 Nov; 160(2):297-304. PubMed ID: 27704226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rising Bilateral Mastectomy Rates Among Neoadjuvant Chemotherapy Recipients in California From 1998 to 2012.
    Wapnir IL; Kurian AW; Lichtensztajn DY; Clarke CA; Gomez SL
    Ann Surg; 2017 Aug; 266(2):353-360. PubMed ID: 27611617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Breast Cancer Treatment Delays on Survival Among South African Women.
    Pumpalova YS; Ayeni OA; Chen WC; Buccimazza I; Cačala S; Stopforth LW; Farrow HA; Mapanga W; Nietz S; Phakathi B; Joffe M; McCormack V; Jacobson JS; Crew KD; Neugut AI; Ruff P; Cubasch H; O'Neil DS
    Oncologist; 2022 Mar; 27(3):e233-e243. PubMed ID: 35274708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disparities at the Intersection of Race and Ethnicity: Examining Trends and Outcomes in Hispanic Women With Breast Cancer.
    Champion CD; Thomas SM; Plichta JK; Parrilla Castellar E; Rosenberger LH; Greenup RA; Hyslop T; Hwang ES; Fayanju OM
    JCO Oncol Pract; 2022 May; 18(5):e827-e838. PubMed ID: 33026950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Treatment Sequence in Patients With Stage III Breast Cancer.
    Ntowe KW; Thomas SM; Dalton JC; Chiba A; Woriax HE; DiLalla G; DiNome ML; Plichta JK
    J Surg Res; 2024 Oct; 302():347-358. PubMed ID: 39146842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy.
    Ryu YJ; Kang SJ; Cho JS; Yoon JH; Park MH
    Medicine (Baltimore); 2018 Jul; 97(30):e11647. PubMed ID: 30045313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients.
    Sanford RA; Lei X; Barcenas CH; Mittendorf EA; Caudle AS; Valero V; Tripathy D; Giordano SH; Chavez-MacGregor M
    Ann Surg Oncol; 2016 May; 23(5):1515-21. PubMed ID: 26678405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy.
    Mittendorf EA; Buchholz TA; Tucker SL; Meric-Bernstam F; Kuerer HM; Gonzalez-Angulo AM; Bedrosian I; Babiera GV; Hoffman K; Yi M; Ross MI; Hortobagyi GN; Hunt KK
    Ann Surg; 2013 Feb; 257(2):173-9. PubMed ID: 23291658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of neoadjuvant chemotherapy on breast reconstruction.
    Hu YY; Weeks CM; In H; Dodgion CM; Golshan M; Chun YS; Hassett MJ; Corso KA; Gu X; Lipsitz SR; Greenberg CC
    Cancer; 2011 Jul; 117(13):2833-41. PubMed ID: 21264833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05).
    Shim SJ; Park W; Huh SJ; Choi DH; Shin KH; Lee NK; Suh CO; Keum KC; Kim YB; Ahn SD; Kim SS; Ha SW; Chie EK; Kim K; Shin HS; Kim JH; Lee HS
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):65-72. PubMed ID: 24161425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial.
    Yamaguchi T; Hozumi Y; Sagara Y; Takahashi M; Yoneyama K; Fujisawa T; Osumi S; Akabane H; Nishimura R; Mieno MN; Mukai H
    Surg Oncol; 2021 Mar; 36():51-55. PubMed ID: 33310293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Affecting Time to Surgery in Breast Cancer Patients.
    Chagpar AB; Howard-McNatt M; Chiba A; Levine EA; Gass JS; Gallagher K; Lum S; Martinez R; Willis AI; Fenton A; Solomon NL; Senthil M; Edmonson D; Namm JP; Walters L; Brown E; Murray M; Ollila D; Dupont E; Garcia-Cantu C
    Am Surg; 2022 Apr; 88(4):648-652. PubMed ID: 34732082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy.
    Pollom EL; Qian Y; Chin AL; Dirbas FM; Asch SM; Kurian AW; Horst KC; Tsai CJ
    Int J Cancer; 2018 Dec; 143(12):3262-3272. PubMed ID: 29992582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.